Introduction
Ferrochelatase catalyzes the formation of heme by chelating ferrous iron to protoporphyrin IX. High ferrochelatase activity is required during erythropoiesis to provide heme for hemoglobin, but low constitutive activity is required in all cell types to provide heme for cytochromes and other essential heme-containing proteins. The ferrochelatase gene is located on chromosome 18, and consists of 11 exons spanning about 40-50 kilo bases in both mouse and man 1-4 . Mammalian ferrochelatase is a metallo-enzyme that possess a 2-iron/2-sulfur cluster, a structural component of the protein which is located near the carboxyl terminus and is required for enzymatic activity 5 . The ferrochelatase protein is translated with a mitochondrial targeting peptide, which is cleaved off after translocation of the enzyme to its active site in the inner mitochondrial membrane 6,7 . The mammalian enzyme is active in situ as an 80-82 kD homodimer as suggested by radiation inactivation studies 8 and confirmed by X-ray crystallography 9,10 .
Protoporphyria is a disease caused by a deficiency in ferrochelatase activity 11 . The principal clinical manifestation of protoporphyria is severe photosensitivity and in rare cases hepatobiliary disease, which can advance to hepatic failure and require liver transplantation 12 .
The symptoms of protoporphyria are due to the partial enzymatic block, which results in excess protoporphyrin that accumulates in tissues, serum and bile 13, 14 . Approximately 80% of the excess protoporphyrin originates from developing erythroid cells and 20% from the liver 15 .
Cutaneous photosensitivity occurs when the excess protoporphyrin in the skin is excited by sunlight (or wavelengths of 400-410 nm), which concomitantly results in tissue-damaging production of free-radicals and reactive oxygen species 16, 17 . Hepatic protoporphyria results For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From feature of dominantly inherited protoporphyria is that enzyme activities are consistently reported at 15% to 30% of normal and not 50% as might be expected for a dominantly inherited disorder.
Two models have been proposed to explain this less-than-50% activity. The "dominant-negative" model maintains that a mutant ferrochelatase monomer interacts with a wild type monomer in a dominant-negative manner to decrease enzymatic activity levels lower than 50% of normal 37 .
The "low-expressing allele" model suggests that a null allele in combination with a lowexpressing allele (with a wild type coding region) decreases ferrochelatase activities to lower than 50% of normal 38,39 .
In a previous study, the "dominant-negative model" was tested by introducing an exon 10-deletion into the mouse genome via homologous recombination in mouse embryonic stem cells (ES) 47 . In ferrochelatase heterozygous ES cells, ferrochelatase protein levels and activities were consistently 50% of normal, suggesting that a second mutation is required to bring the enzymatic activity levels to those observed in human protoporphyria.
In this study the molecular, biochemical and pathophysiologic effect of the exon 10-deletion mutation was assessed in vivo by generating mice that were heterozygous for the mutation. Exon 10-deleted mRNA expression patterns in erythroid and non-erythroid tissues were determined, the wild type and exon 10-deleted ferrochelatase protein was characterized by immunoblotting and mitochondrial activity assays. Erythrocyte and bile protoporphyrin levels were determined and the clinical phenotype was assessed in heterozygous mice. Unlike studies in ES cells, in vivo ferrochelatase activities in heterozygous mice were less than 50% of normal resulting in protoporphyrin accumulation and photosensitivity. 
Materials and Methods

ES Targeting and Breeding
To introduce an exon 10 deletion into the mouse ferrochelatase gene, a targeting construct was designed that upon homologous recombination with the ferrochelatase gene would replace exon 10 with the neomycin gene selectable marker ( figure 1A ). The splice donor site for exon 9 and splice acceptor site for exon 11 remained intact so that the neomycin gene would be spliced out of the pre-mRNA resulting in the in-frame joining of exon 9 to exon 11. ES cells heterozygous for the exon 10 deletion were generated by electroporating the targeting construct into the BK4 cell line (a subclone of E14TG2a), and selecting with geneticin (200 µg/ml) and ganciclovir (0.5 µg/ml) for 10 days. Individual geneticin resistant and ganciclovir insensitive clones were expanded and tested for correct targeting by Southern blot 47,48 . Heterozygous ES cells were injected into day 3, C57B6 strain blastocysts. Chimeric mice were crossed to C57B6 mice, and agouti, F1 offspring were tested for the genomic deletion of exon 10 using PCR. F1 heterozygous mice were then inter-crossed to obtain F2 progeny for developmental analysis. For all other experiments, F1 heterozygotes were crossed to C57B6 strain mice. Wild type littermates were used as controls for all experiments.
Genotyping
For PCR genotyping of F1 and F2 progeny, primers were designed that would either amplify the wild type allele (PR3 and PR2) or the exon 10-deleted allele (PR1 and PR2) ( figure   1A ). Genomic DNA (gDNA) was isolated from mouse tails using standard methods 49 , and 1 µg of gDNA was added to a PCR reaction containing the gene specific primers: PR1(NEO) 3'-CTG CTC GAC ATT GGG TGG AAA-5', PR2(exon 11) 3'-GAA GGA TTT AGT CTT CCT GCA- For embryo studies, heterozygous mice were crossed to generate exon 10-/-progeny. Preimplantation embryos were collected at 3.5 days of gestation. The blastocysts were flushed from the uterus, collected in DMEM-H medium containing 10% FCS, 2 mM L-glutamine and 100 U/ml penicillin, 1 mg/ml streptomycin, and transferred twice to new medium to separate blastocysts from contaminating maternal cells. Individual blastocysts were placed in 20 µl of lysis buffer (50 mM KCl, 1.5 mM MgCl 2 , 10 mM Tris-HCl (pH-8.3), 0.45% Tween-20, 0.45% NP-40 and 100 µg/ml proteinase K) and incubated at 50°C for 2 hours, and then incubated at 100°C for 10 minutes to destroy the proteinase K. PCR genotyping was carried out using the primers and buffer already described. To amplify the wild type and mutant alleles, 2 µl of the blastocyst lysate was used as template in a 34 cycle reaction (94°C, 15 sec.;54°C 15 sec.;72°C 30 sec.) for the wild type allele, and 45 cycle reaction (97°C, 15 sec; 54°C, 15 sec; 72°C, 1.5 min.) for the exon 10-deleted allele.
Late-gestation embryos were collected in utero at 9-10 d.p.c. The entire uterus was fixed in formalin for 24 hours, then transferred to 70% ethanol before sectioning. To collect tissue for genotyping day 9-10 embryos, the cover-slips from the stained sections were removed by soaking in xylene for 24 hours. Then, an area of tissue about 1-2 mm in diameter from each embryo was scraped from the slide using a tuberculin needle. The tissue was then placed in 50 µl proteinase K buffer (see above) and incubated at 56°C for 30 minutes. The DNA mixture was heated to 100°C for 10 minutes to inactivate the proteinase K and then centrifuged at 12,000 rpm only.
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mRNA Analysis
To assess the expression of the exon 10-deleted ferrochelatase allele in a non-erythroid and erythroid tissue, we amplified cDNA made from liver (non-erythroid) and spleens For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From glycerol, and frozen at -80°C until assayed.
To determine ferrochelatase protein levels in mitochondrial extracts, 50 µg of mitochondrial protein was separated on a 10% SDS-PAGE gel. The proteins were electrophoretically transferred from the gel to pure nitrocellulose membrane (S&S, Keene, NH).
Equal loading of protein was assessed by Ponceau S staining. The membrane was then blocked with BLOTTO (5% w/v non-fat dried milk in water) for 15 minutes at room temperature. Then, an anti-recombinant human ferrochelatase polyclonal antibody 53 was applied at a 1:500 dilution in BLOTTO to the membrane and allowed to incubate at room temperature for 16 hours. 
Ferrochelatase activity
Ferrochelatase activity was determined essentially as described 47 . Liver mitochondrial lysates were sonicated twice in a Branson sonicator for 10 seconds and incubated on ice. The enzymatic chelation of zinc and mesoporphyrin was carried out in a reaction that contained 25 µg of mitochondrial lysate, 50 µM zinc acetate, and 50 µM mesoporphyrin in palmitic acid buffer 47 . The reaction was incubated at 37°C in the dark. After 30 minutes, 1.0 ml of ice cold 8:2 methanol/DMSO (dimethyl sulfoxide) was added to stop the reaction. The reaction mixture only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From was centrifuged for 10 minutes at 12,000 x g. To detect the zn-mesoporphyrin reaction product, 20 µl of the supernatant was loaded onto a Delta PAK, 5 µm, C 18 300 Å, HPLC column (Waters, Milford, MA) and separated in an 88% methanol, 12% 1 M ammonium acetate (pH 5.16) mobile phase with a 1.25 ml/minute flow rate. The column flow-through was directed into the flow cell adapter of the LS50B spectrofluorimeter (Perkin-Elmer), which was set to an excitation wavelength of 403 nm and an emission wavelength of 574 nm. Concentrations of zincmesoporphyrin were determined by comparing samples to a standard curve derived from zincmesoporphyrin standards (Porphyrin Products, Logan, UT).
Determination of free erythrocyte and bile protoporphyrin levels
Levels of protoporphyrin in erythrocytes and bile were determined using HPLC separation of pigments followed by spectrofluorimetry 54,55 . After a 12 hour fast to induce bile accumulation, mice were euthanized by cervical dislocation. Bile and whole blood were collected, and 10 µl of whole blood (in sodium heparin) was set aside for the determination of free erythrocyte protoporphyrin levels. To extract protoporphyrin from the samples, 2.5 µl of bile or whole blood was added to 250 µl of 0.9N perchloric acid/methanol (1:1 v/v), briefly vortexed, and centrifuged at 12,000 x g to pellet the precipitated protein. Two hundred µl of the supernatant was applied to a reverse-phase HPLC column and separated in an elution gradient consisting of 0.1M sodium phosphate (pH 3.5)/methanol mobile phase. The flow rate was 1.25 ml/min, and the injections were initiated when the gradient was 45% methanol/55% sodium phosphate. Immediately after sample injection, a linear gradient was initiated and held for two minutes. The gradient ended at 95% methanol/5% sodium phosphate, then, a reverse gradient was initiated which brought the mobile phase back to original conditions (45% methanol/55% sodium phosphate) over a 1 minute period. Protoporphyrin was quantified fluorometrically by only.
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Protoporphyrin concentrations in the samples were determined using a standard curve derived from protoporphyrin standards (Porphyrin Products, Logan, UT).
Fluorescence microscopy was used to visually assess protoporphyrin accumulation in erythrocytes. A smear was made with 1 µl of tail vein blood. The erythrocytes were observed using an Olympus IX70, 200X magnification, 405 nm excitation filter and a 620 nm emission filter.
Photosensitization
Normal and heterozygous mice (approximately 14 months of age) were depilated using Nair TM and were exposed to mercury vapor lamp light at a distance of 20 cm 56,57 . A piece of shielding glass was placed between the lamp and the mouse to block ultraviolet-B and -C light.
Initial experiments, using a 20-minute exposure time, produced no photosensitivity. Thirtyminute exposures were determined to be the minimum time required to elicit photosensitivity, which was first observed 48-72 hours after exposure. Images of light exposed skin were captured using a Nikon Cool Pix-990 digital camera (Nikon, Melville, NY, USA ).
only.
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Results
Homozygosity of the exon 10-deletion is embryonic lethal
To introduce an exon 10 deletion into the mouse ferrochelatase gene, we designed a targeting construct that upon homologous recombination with the ferrochelatase gene would replace exon 10 with the neomycin gene selectable marker ( figure 1A) . The splice donor site for exon 9 and splice acceptor site for exon 11 remained intact so that the neomycin gene would be spliced out of the pre-mRNA resulting in the in-frame adjoining of exon 9 to exon 11 ( figure   1B ). The targeting ratio for this region of the mouse ferrochelatase locus was 1 homologous recombination to 4 random integrations.
Chimeric mice were generated by injecting heterozygous ES cells into day 3, C57B6 strain, blastocysts. Mice heterozygous for the ferrochelatase exon 10-deletion were crossed to obtain an F2 generation in which the observed genotype was a ratio of 1 wild type to 2 heterozygotes. No homozygous mice were observed in 10 separate breedings (producing over 100 progeny).
To further investigate whether there were any embryos homozygous for the mutation, embryos that were at 9-10 days of gestation were collected and histologically analyzed. In two separate breedings of heterozygous mice, one out of four embryos were being re-absorbed. There were no anatomical structures that could be used to determine the day of lethality. No embryonic abnormalities were observed in control breedings using wild type mice. To confirm the presence of early-stage homozygous embryos, pre-implantation embryos were collected at day 3.5 of gestation. PCR genotype analysis demonstrated that 4 of 26 blastocysts were homozygous for the exon 10-deletion. 
Equal amounts of mutant and wild type ferrochelatase protein, but reduced enzyme activity in heterozygous mice
To examine ferrochelatase protein in the heterozygous mice, we conducted immunoblotting assays using an anti-human ferrochelatase antibody that cross-reacts with mouse ferrochelatase ( figure 3A ). An immuno-reactive protein that corresponds to the size of wild type ferrochelatase appeared in extracts from both normal and heterozygous mice. However, in heterozygous mice there was also a unique, fast migrating band that corresponded to the size of an exon 10-deleted ferrochelatase protein. To assess ferrochelatase activity in heterozygous and wild type mice, we measured the enzymatic chelation rate of zinc and mesoporphyrin ( Figure 3B ). The hepatic mitochondrial ferrochelatase activity in heterozygous mice was an average of 37% ± 8% of normal control mice activities. The ferrochelatase activities in heterozygous mice were significantly decreased compared to 50% activities of wild type mice (p<0.002), consistent with the mutant allele having a dominant-negative effect on the wild type allele.
Increased protoporphyrin levels in ferrochelatase heterozygous mice
Fluorescence microscopy and spectrofluorimetry were used to determine if there was an accumulation of protoporphyrin in heterozygous mice. Peripheral whole blood was observed microscopically using wavelengths that excite protoporphyrin (405 nm). Red fluorescence was observed in the erythrocytes of heterozygous mice, but not observed in the erythrocytes of normal control mice (figure 4A).
To quantify the accumulated protoporphyrin in the erythrocytes, we extracted erythrocyte porphyrins from wild type and heterozygous mice and determined protoporphyrin levels using HPLC combined with spectrofluorimetry (figure 4B). Protoporphyrin levels were an average of 9 ± 2-fold higher in erythrocytes of heterozygous mice compared to normal mouse erythrocytes (p<0.001).
Secretion of protoporphyrin into bile is the primary elimination route of excess protoporphyrin 18,19 . To determine if there were increased levels of protoporphyrin in the bile of heterozygous mice, we assessed protoporphyrin levels by separating the bile porphyrins using HPLC with subsequent spectrofluorimetric quantification. Bile protoporphyrin levels in heterozygous mice were found to be an average of 2.2 ± 0.7-fold higher (p<0.001) than that of normal mice ( figure 4C) . only.
Heterozygous mice exhibit skin photosensitivity
Patients with protoporphyria exhibit photosensitivity of varying levels and severity. To assess whether heterozygous mice exhibited photosensitivity, both heterozygous and normal control mice (14 months of age) were depilated and exposed to light from a U.V.-shielded mercury vapor lamp. There was no acute photosensitivity observed immediately following light exposure in either the heterozygous mice or controls. However, 48 to 72 hours after light treatment, heterozygous mice exhibited severe edema and necrosis of the skin on their depilated backs (figure 5). Additionally, tissue necrosis was observed on the ear tips of heterozygous mice, but not in normal control mice ( figure 5C ). only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From disease 15,58 . To determine if there was hepatic damage in heterozygous mice (2 months and 8-12 months of age), livers were resected, fixed, sectioned and stained with hematoxylin/eosin, a collagen-specific stain and a bile-specific stain. In both heterozygous and control mice, the liver architecture was normal, and there were no signs of cholestasis or fibrosis. Results from the electron-microscopy studies indicated no protoporphyrin microcrystals, a hallmark feature of hepatic protoporphyria 59-61 , in hepatocytes of heterozygous mice. Additionally, there were no significant differences in the AST and ALT levels in heterozygous mice compared to controls.
Discussion
The aim of this study was to introduce a well-described mutation identified in human protoporphyria into the mouse ferrochelatase gene to determine the in vivo effect of the mutation at the molecular, biochemical and pathophysiologic levels.
A breeding scheme designed to generate mice that were homozygous for the exon 10-deletion failed to produce progeny that possessed a homozygous mutant genotype. It was predicted that exon 10-/-mice would not be viable, since non-enzymatic heme production would be insufficient for the synthesis of hemoproteins. It was a question, however, whether nonenzymatic chelation of iron and protoporphyrin would provide sufficient levels of heme for viability prior to a developmental stage that required erythrocytes. In matings of heterozygotes, we made an observation that embryos were being re-absorbed at a ratio of 1:4 in the uteri of mice (9-10 days post-coitus). The proportion of non-viable (-/-) to viable (+/+ or +/-) embryos based on Mendelian genetics suggested all exon 10-deleted homozygotes were dead by day 9 postcoitus. Because tissue from embryos being re-absorbed was contaminated by maternal cells, we were unable to genotype these remnants. Studies on embryos from an earlier gestational stage indicated that exon 10-/-embryos were viable until at least day 3.5 of gestation suggesting that lethality occurs between day 4 (implantation) and day 9. Thus, we speculate that a homozygous mutant embryo could implant and develop for a finite period.
Protoporphyria is inherited as an autosomal dominant trait, but the enzymatic activity is 5%-30% of normal and not the expected 50%. Thus, we have hypothesized that the mutant protein has a "dominant negative" effect on the wild type protein. In order for a mutant ferrochelatase monomer to exert a "dominant-negative" effect on the ferrochelatase dimer, there would need to be sufficient levels of mutant monomers to dimerize with wild type monomers.
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Nearly equivalent amounts of the mutant and wild type mRNAs were observed in the livers and spleens of exon 10+/-mice, and immunoblot analysis of mitochondrial extracts demonstrated immuno-reactive material that corresponded to the size of the wild type and exon 10-deleted ferrochelatases at a 1:1 ratio ( figure 3A) . These results indicate that the exon 10-deleted ferrochelatase is in a stoichiometric quantity that could produce a measurable dominant-negative effect.
We were able to rule out that the 37% ferrochelatase activities were due to differences in the wild type allele expression from the hybrid mouse strain. The exon 10-deletion was on the ferrochelatase allele derived from the 129/Ola strain and the wild type ferrochelatase allele was derived from C57B6 strain. Because the hybrid heterozygotes (129/C57B6) were always crossed to the C57B6 pure strain, wild type ferrochelatase expression was derived from the wild type C57B6 allele in both normal and heterozygous mice. Therefore, the 37% ferrochelatase activities observed in the heterozygous mice suggests that the exon 10-deleted ferrochelatase is decreasing ferrochelatase activity by a dominant-negative mechanism and not by lower allelic expression.
In a previous study we analyzed ferrochelatase mRNA and protein from exon 10+/-ES cells in culture 47 . In contrast to the results in mice, studies in ES cells demonstrated that greater than 90% of the ferrochelatase mRNA originated from the wild type allele. Additionally, no exon 10-deleted protein was observed using immunoblot assays. These observations indicate there is a differential stability of the mutant ferrochelatase mRNA and/or protein in different cell lineages.
The lack of an exon 10-deleted ferrochelatase provides a reasonable explanation as to why we did not observe less-than-50% ferrochelatase activity in exon 10+/-ES cells.
In patients with protoporphyria the erythrocyte protoporphyrin levels are increased 9.3-to 98-fold higher than normal controls 62 and bile protoporphyrin concentrations are increased 5-to only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From 161-fold higher than normal controls 63 . Likewise, in heterozygous mice, we observed increased levels of protoporphyrin in erythrocytes (9-fold) and bile (2.2-fold) (figure 4). Data in this study show that erythrocytic protoporphyrin levels from heterozygous mice are within the range of erythrocyte protoporphyrin levels observed in patients with protoporphyria. Although bile protoporphyrin levels in the 10+/-mice are increased above controls, the accumulation is less than that observed in patients with protoporphyria.
Biochemical and histological analysis of exon 10+/-mouse livers demonstrated that protoporphyrin had not reached sufficient levels to produce hallmark features of hepatic protoporphyria. Since the 37% ferrochelatase activities in the exon 10-deleted mouse are generally higher than those observed in patients with protoporphyria, it is likely that protoporphyrin accumulation is less than that in patients with protoporphyria; thus, serum protoporphyrin can be efficiently extracted by the liver and secreted into bile, without accumulating and causing liver injury. Serum protoporphyrin levels in exon 10-deleted mice were below the detection limit of the assay, consistent with the proposed complete biliary excretion.
Hepatic protoporphyria has been demonstrated in a homozygous mouse model for protoporphyria (Fechm1Pas) 64 . The mutagen-induced defect in these mice was characterized as a point-mutation that decreased ferrochelatase activity to approximately 50% in heterozygous mice and 2.5% -6% in homozygous mice 65 . Heterozygous mice showed no signs of liver disease, whereas, homozygous mice presented with cholestasis and severe hepatic dysfunction.
The levels of ferrochelatase activity in the Fechm1Pas mouse are approximately 1/8th of the levels in mice with the exon 10 deletion. These data suggest that ferrochelatase activities of 37% and the resulting protoporphyrin production are not sufficient to accumulate in the liver and only.
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Protoporphyrin levels were sufficiently high in the heterozygous mice to elicit photosensitivity. Mice that were 14 months of age were exposed to mercury-vapor lamp light, which has a high output in the 400 nm range. Three of three heterozygous mice showed light induced lesions that were absent in control mice (figure 5) indicating that ferrochelatase activities of 37% of normal result in protoporphyrin accumulation that is adequate to produce light induced lesions.
Theoretically, if a dominant-negative interaction existed that abolished all enzymatic activity from a heterodimer, there would still remain 25% of normal activity from the wild type homodimers. Because some patients with protoporphyria exhibit activities less than 25% of normal, it is probable that a second mechanism exists that would decrease enzymatic activity to Since highly variable ferrochelatase activities are described in patients with protoporphyria, it is probable that multiple modulating factors are involved in the molecular pathogenesis of this disease. The combined effects of both a dominant-negative ferrochelatase and a low-expressed allele could explain the wide variations in ferrochelatase activities observed in patients with protoporphyria. It is possible that only certain mutant ferrochelatase monomers are able to exert a dominant-negative effect on the ferrochelatase dimer, or that the level of the dominant-negative effect varies between different exon-deleted ferrochelatases. Therefore, it will be necessary to functionally study the interaction of various mutant monomers with wild type ferrochelatase monomers to verify the existence of, and contribution to, a dominant-negative interaction.
The exon 10-deleted mouse model demonstrates that a heterozygous exon 10-deletion is sufficient to cause the enzymatic, biochemical and some clinical manifestations of protoporphyria. Because the ferrochelatase exon 10-deleted mouse model demonstrates ferrochelatase activities that are near the threshold of phenotypic expression of protoporphyria, the heterozygous animal model will be useful for studying the effect of contributory genetic or environmental factors which modulate the protoporphyric phenotype. only.
